Compare SOHU & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOHU | ARMP |
|---|---|---|
| Founded | 1996 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.8M | 295.5M |
| IPO Year | 2018 | 1996 |
| Metric | SOHU | ARMP |
|---|---|---|
| Price | $12.23 | $7.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $20.00 | $15.00 |
| AVG Volume (30 Days) | 46.0K | ★ 54.7K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.61 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $1.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.12 | $1.81 |
| 52 Week High | $17.30 | $14.98 |
| Indicator | SOHU | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 28.54 | 38.34 |
| Support Level | N/A | $4.96 |
| Resistance Level | $15.99 | $7.70 |
| Average True Range (ATR) | 0.44 | 0.65 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 14.36 | 36.04 |
Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.